The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s in situ hybridization market report forecasts the in situ hybridization market size to grow to $2.26 Billion by 2027, with a CAGR (compound annual growth rate) of more than 9%.

Learn More On The In Situ Hybridization Market Report 2023 – https://www.thebusinessresearchcompany.com/report/in-situ-hybridization-global-market-report

In Situ Hybridization Market Size Forecast
The global in situ hybridization market is expected to grow from $1.43 billion in 2022 to $1.57 billion in 2023 at a compound annual growth rate (CAGR) of 9.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global in situ hybridization market size is expected to reach $2.26 billion in 2027 at a CAGR of 9.6%.

North America held the largest in situ hybridization market share, and Asia-Pacific was the fastest-growing region in 2022.

Key In Situ Hybridization Market Driver ­– Increase In Infectious Diseases
According to the Annual Epidemiological Report for 2021 published by the European Centre for Disease Prevention and Control, a Sweden-based European government health agency, the distribution of hepatitis C cases and rates per 100,000 population in Germany in December 2022 reached 4,718 cases and 5.7 rates, up from 4,536 cases and 5.5 rates in 2020. As a result, rising infectious diseases are propelling the in-situ hybridization industry forward.

Request for A Sample Of The Global In Situ Hybridization Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10476&type=smp

Key In Situ Hybridization Market Trend – Technological Advancement
To maintain their market position, major businesses in the in-situ hybridization industry are focusing on the development of technologies. For example, in April 2021, Bio-Techne Corporation, a biotech firm based in the United States that manufactures and commercialises science reagents and instruments, introduced RNAscope technology and marketed a new DNAscope Assays. The RNAscope technology is an improved in situ hybridization (ISH) approach that enables direct visualisation of single-molecule transcription in unmodified cells and tissues with single-cell resolution. DNAscope can quickly and easily build probes for any DNA target and allow for target visualisation in formalin-fixed paraffin-embedded (FFPE) tissues because it leverages the tried-and-true ‘double-Z’ probe design and signal enhancement system of RNAscope.

In Situ Hybridization Market Segment
1) By Product: Analytical Instruments, Kits and Reagents, Software and Services, Other Products
2) By Technique: Fluorescence In Situ Hybridization (FISH), Chromogenic In Situ hybridization (CISH)
3) By Probe: Deoxyribonucleic Acid (DNA), Ribonucleic Acid (RNA)
4) By Application: Cancer, Cytogenetics, Developmental Biology, Infectious Diseases, Other Applications
5) By End Use: Research And Diagnostic Laboratories, Contract Research Organization (CROs), Academic Institutes, Other End Uses

In Situ Hybridization Market Major Players and Strategies
Major players in the in situ hybridization market are Thermo Fisher Scientific Inc., Bio SB Inc., BioGenex Laboratories, Advanced Cell Diagnostics Inc., Exiqon A/S, Agilent Technologies Inc., F. Hoffmann-La Roche AG, Abbott Laboratories, Merck KGaA, PerkinElmer Inc., Biocare Medical LLC, Genemed Biotechnologies, Danaher Corporation, Leica Biosystems Nussloch GmbH, and Bio-Rad Laboratories Inc.

PerkinElmer Inc., a life science firm based in the United States that develops and commercialises diagnostic and industrial testing equipment, paid $5.25 billion for BioLegend in September 2021. PerkinElmer’s comprehensive life science platform and powerful global infrastructure will help BioLegend expand its diagnostic business with this acquisition. Furthermore, PerkinElmer’s life science products will be expanded with this acquisition to include cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation, and bioprocessing. BioLegend is a corporation established in the United States that manufactures diagnostic reagents for biomedical research organizations.

The In Situ Hybridization Global Market Report 2023 covers regional data on in situ hybridization market size, in situ hybridization market trends and drivers, opportunities, strategies, and in situ hybridization market competitor analysis. The countries covered in the in situ hybridization market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

In-situ hybridization is a technique that allows for the precise localization of a specific nucleic acid segment within a histologic slice. In-situ hybridization is used to identify nucleotide sequences in tissues, including whole tissues, sections of tissues, and cells.

View More Reports Related To The In Situ Hybridization Market –
Hybrid Cloud Global Market Report 2023
Hybrid Truck Global Market Report 2023
Investigation And Security Services Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: